New Drugs

Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression

Written by David Miller

DUBLIN and BUDAPEST, Hungary, May 28, 2019 /PRNewswire/ — Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Vraylar…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]